ERIC BULLER: Open Payments
NPI 1467423509 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,644 in 82 payments from 35 companies in 2025. Trend: 2023 $1,164 · 2024 $1,257 · 2025 $1,644
Food & beverage: $1,545Education: $99
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 7 | $181 |
| Merck Sharp & Dohme LLC | 5 | $115 |
| Novartis Pharmaceuticals Corporation | 5 | $113 |
| Exelixis Inc. | 5 | $109 |
| AstraZeneca Pharmaceuticals LP | 5 | $91 |
| Janssen Biotech, Inc. | 4 | $75 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
| Incyte Corporation | 3 | $60 |
| Alexion Pharmaceuticals, Inc. | 3 | $56 |
| ABBVIE INC. | 3 | $54 |
Products named: Enhertu, CABOMETYX, KEYTRUDA, REBLOZYL, KISQALI, ULTOMIRIS, BRUKINSA, DATROWAY.
Industry payments across LA — which companies pay providers there.
